Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/lt.25961 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety and Effectiveness of BPaL-Based Regimens to Treat Multidrug-Resistant TB: First Experience of an Italian Tuberculosis Referral Hospital.
Antibiotics (Basel)
December 2024
Respiratory Infectious Diseases Unit, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, 00149 Rome, Italy.
: Tuberculosis (TB) is preventable and curable, but multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) pose significant challenges worldwide due to the limited treatment options, lengths of therapies, and high rates of treatment failure. The management of MDR-TB has been revolutionized by all oral anti-TB drug regimens that are likely to improve adherence and treatment outcomes. These regimes include bedaquiline (B), pretomanid (P), and linezolid (L) (BPaL), and moxifloxacin if resistance to fluoroquinolones is not detected (BPaLM).
View Article and Find Full Text PDFCharacteristics of Pseudomonas aeruginosa keratitis at Ho Chi Minh eye hospital.
Int Ophthalmol
December 2024
University of Medicine and Pharmacy, Ho Chi Minh City, Vietnam.
Background: The increasing drug resistance of Pseudomonas aeruginosa (PA) poses a serious challenge to the current treatment. Antibiograms of this pathogen often take 3-5 days, and treatment of Pseudomonas aeruginosa keratitis (PAK) is mainly based on preliminary physical examination, clinical experience, and medical guidelines. Pertinent clinical data on the causative agent and antibiotics for high efficacy are essential for early recognition and subsequent treatment.
View Article and Find Full Text PDFExperience of piloting BPaLM/BPaL for DR-TB care at selected sites in Pakistan.
IJTLD Open
November 2024
Association for Social Development, Islamabad, Pakistan.
Background: Pakistan ranks fourth globally in terms of high drug-resistant TB (DR-TB) burden, with approximately one-third of cases resistant to fluoroquinolones. Bedaquiline, pretomanid, linezolid and moxifloxacin (BPaLM/BPaL) offers an opportunity for most DR-TB patients to benefit from a shorter, all-oral, well-tolerated and more effective treatment.
Methods: We conducted a retrospective cohort study to pilot the BPaLM/BPaL regimen at four selected sites in two provinces of Pakistan, i.
Pneumocystis jirovecii and Nocardia pneumonia in a middle-aged male with Nephrotic syndrome: a case report and literature review.
BMC Infect Dis
September 2024
Department of Nephrology, Baoding No 1 Central Hospital of Hebei Medical University, Baoding Great Wall North Street No 320, Baoding, Hebei, 071000, China.
Article Synopsis
- Nephrotic syndrome is a kidney disease that can make people more likely to get infections, especially from two germs called Pneumocystis jirovecii and Nocardia brasiliensis.
- A 58-year-old man with this disease got very sick and had a tough time finding out what was wrong until doctors used a special test called mNGS, which helped them find the exact germs causing his illness.
- The patient received a special treatment plan that worked really well, showing that new testing technology can help doctors find and treat infections faster.
Impact of bedaquiline resistance probability on treatment decision for rifampicin-resistant TB.
IJTLD Open
September 2024
Department of Family Medicine and Population Health, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
Background: Accurate diagnosis of bedaquiline (BDQ) resistance remains challenging. A Bayesian approach expresses this uncertainty as a probability of BDQ resistance (prBDQ) with a 95% credible interval. We investigated how prBDQ information influences BDQ prescribing decisions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!